CSBio CSBio

X
[{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma and Solarvest Enhance Commitment to CBD Research Project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"FSD Pharma"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"BetterLife Pharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"InMed Pharmaceuticals"},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Avicanna"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Raya Therapeutic Announces Early-Stage R&D Collaboration with Argenx","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Raya Therapeutic"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration aims to focus on testing combinations of Raya's pipeline of targeted small molecules with a potentially complementary product from argenx.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Argenx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Oral administration of cannabinoids is the most convenient route for non-invasive drug delivery. Avicanna intends to conduct further pre-clinical studies in the coming months in order to formalize this provisional application and will incorporate the technology.

            Lead Product(s): Cannabinoid

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 06, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The PCT application demonstrate cannabinoid compound inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection also can be used to promote neurite outgrowth, signifying the potential to enhance neuronal function.

            Lead Product(s): Cannabinoid

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 03, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration for treatment of neurodegenerative disorders.

            Lead Product(s): mRNA Antibody

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BetterLife has filed patent protection on the newest compound to enter its pipeline, dihydrohonokiol-B (“TD-010”). Specifically, BetterLife has filed for patent protection for the use of TD-010 as a treatment for sedative, hypnotic, or anxiolytic use disorder.

            Lead Product(s): Dihydrohonokiol-B

            Therapeutic Area: Neurology Product Name: TD-010

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project.

            Lead Product(s): Cannabinoid

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Solarvest BioEnergy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY